Effect of valve design and anticoagulation strategy on 30-day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial.
Axel LinkeJaya ChandrasekharSamantha SartoriThierry LefevreEric van BelleUlrich SchaeferDidier TchetcheGennaro SardellaJohn WebbAntonio ColomboStephan WindeckerBirgit VogelSerdar FarhanSabato SorrentinoMadhav SharmaClayton SnyderAnita AsgarNicolas DumonteilCorrado TamburinoUlrich HinkRoberto VioliniPieter StellaDebra BernsteinEfthymios DeliargyrisChristian HengstenbergUsman BaberRoxana MehranProdromos AnthopoulosGeorge D Dangasnull nullPublished in: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2017)
Majority of patients in the BRAVO 3 trial received BE valves. At 30-days, adjusted risk of clinical outcomes was similar with non-BE vs. BE valves. A significant interaction was observed between valve type and procedural anticoagulant for lower risk of major vascular complications with bivalirudin versus UFH in non-BE TAVR.
Keyphrases
- aortic valve
- transcatheter aortic valve replacement
- aortic stenosis
- aortic valve replacement
- ejection fraction
- transcatheter aortic valve implantation
- atrial fibrillation
- end stage renal disease
- venous thromboembolism
- newly diagnosed
- chronic kidney disease
- study protocol
- heart failure
- prognostic factors
- mitral valve
- coronary artery disease
- phase iii
- phase ii